RxDoctor Payments Data

Michael Papenfuse, DO

Interventional Pain Medicine · Saginaw, MINPI 1528067360

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,095 of the $6,158 with a category attached, or 66.5%. 18 manufacturers reported payments, led by Vertiflex, Inc. at 31.1% of the total. Reporting peaked in 2019 at $2,198 and has fallen 76.6% since, to $514 in 2025.

$6,158in general payments, 2019–2025

Across 127 payments — averaging $48.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertiflex, Inc.$2K
  • Nevro Corp.$2K
  • Medtronic$846
  • Boston Scientific$589
  • Relievant Medsystems, Inc.$262
  • Globus Medical$219
  • plus $637 from 12 others

What the payments were for

  • Travel & lodging$2,06434%
  • Food & beverage$4,09566%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,158 in reported general payments places this provider in the 70th percentile of 88 interventional pain medicine providers in Michigan.

See all interventional pain medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$142,140
Medicare patients
232
Services billed
1,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl38$43,422
Buprenorphine72$17,630
Fentanyl138$14,765
Xtampza ErOxycodone Myristate11$12,971
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen330$6,397
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen147$4,732
Morphine Sulfate ErMorphine Sulfate121$4,071
Buprenorphine Hcl97$3,659
Oxycodone Hcl161$3,198
Gabapentin136$3,134
Pregabalin66$2,294
Methadone Hcl83$1,344
Tizanidine Hcl92$935
Baclofen30$729
Duloxetine Hcl48$610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$23$12,97111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 88 interventional pain medicine providers in Michigan.

Other interventional pain medicine in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →